View Financial HealthChain Bridge I 配当と自社株買い配当金 基準チェック /06Chain Bridge I配当金を支払った記録がありません。主要情報n/a配当利回り48.1%バイバック利回り総株主利回り48.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2026, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 19Chain Bridge I Receives Notice of OTCQB Delisting and Transfer to OTCID Basic MarketAs previously disclosed, on November 12, 2025, Chain Bridge I (the “Company”) received a written notice from the OTC Markets Group (“OTC”) notifying the Company that, because the Company’s public float as it is currently displayed on the Company profile is less than 10% of the total shares outstanding, the Company is not currently in compliance with the public float requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in Section 2 of the OTCQB listing. On February 11, 2026, the Company received a written notice from OTC indicating that the cure period has now expired. Consequently, the Company’s securities were moved from the OTCQB market to the OTCID Basic Market (“OTCID”) on February 12, 2026. OTC further notified the Company that if it would like to be moved back to OTCQB, it must increase public float to at least 10% of the total shares outstanding and meet all of the eligibility requirements under Section 1 of the OTCQB listing standards. The Company will continue to file its periodic reports and remain subject to the reporting obligations under the Securities Exchange Act of 1934. The Company is actively evaluating strategic options to regain compliance with relevant listing standards and remains committed to upholding transparency and stability for all stakeholders.お知らせ • Sep 09CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025.CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025. Under the terms of the LOI, CBRRF and CommLoan would become a combined entity, with CommLoan’s existing equity holders rolling 100% of their equity into the combined public company. Upon the closing of the transaction, the combined company will be named CommLoan Inc., and would be led by CommLoan’s founder and CEO, Mitch Ginsberg. The new company’s common stock is expected to be listed on the Nasdaq Capital Market. CBRRF expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected later in Q4 2025. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by acquirer board, approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The expected completion of the transaction is in first half of 2026.お知らせ • Jun 22Chain Bridge I Auditor Raises 'Going Concern' DoubtChain Bridge I filed its Annual on Jun 20, 2025 for the period ending Dec 31, 2024. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.お知らせ • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2025, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 20Chain Bridge I(OTCPK:CBRR.F) dropped from NASDAQ Composite IndexChain Bridge I has been removed from NASDAQ Composite Index.お知らせ • Nov 15Chain Bridge I announced delayed 10-Q filingOn 11/14/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 13Chain Bridge I to be Delisted from The Nasdaq Stock Market Due to Non-Compliance with Listing Rule IM-5101-2On November 12, 2024, Chain Bridge I (the ‘Company’) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (‘Rule IM-5101-2’), the staff of Nasdaq (‘Staff’) had determined that (i) the Company’s securities will be delisted from Nasdaq, (ii) trading of the Company’s Class A common stock and units will be suspended at the opening of business on November 19, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by November 4, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now subject to delisting.お知らせ • Aug 16Chain Bridge I announced delayed 10-Q filingOn 08/15/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 23Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction.Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction on July 22, 2024. Under the terms of the Business Combination Agreement, the aggregate consideration to be paid in the Business Combination is derived from an equity value of $58 million. In addition, HoldCo will issue 17,000 shares of HoldCo Series A convertible preferred stock and issue additional shares of HoldCo preferred stock in exchange for certain short term debt obligations of the Company. HoldCo will also pay an earnout consideration which is, upon the occurrence of Triggering Event I, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 2,000,000 Earnout Shares; and upon the occurrence of Triggering Event II, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 1,000,000 Earnout Shares. Upon the closing of the business combination, and assuming no redemptions of shares of CBRG by its public stockholders, Phytanix would expect to receive up to $11 million of cash held in Trust. The business combination is not subject to a minimum cash condition. The parties intend to seek to raise additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time. Upon closing of the transaction, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PHYX.”. The new company will be led by Phytanix Bio’s founders Colin Stott, the former R&D operations director at GW Pharmaceuticals; Dominic Schiller, who formerly led GW’s external IP strategy for more than a decade; and Barrett Evans, managing director at EMC2 Capital. Mr. Barrett Evans will serve as CEO of the combined company; Mr. Colin Stott will serve as Chief Operating Officer; and Mr. Dominic Schiller will lead the legal and IP strategy. Guy Webber, a former GW preclinical team member and world-leading expert in cannabinoids/drug metabolism, will lead preclinical development for the organization. The Boards of Directors of both Phytanix Bio and CBRG have unanimously approved the proposed transaction, including a separate vote by CBRG’s independent directors. The transaction is expected to be completed in the fourth quarter of 2024, pending approval from both CBRG and Phytanix Bio shareholders, the effectiveness of the Registration Statement to be filed by HoldCo, HoldCo having at least $5,000,001 of net tangible assets, the approval by Nasdaq of HoldCo’s initial listing application in connection with the Business Combination, entry into employment agreements with certain key Company executives and entry into an agreement providing for a $100 million equity line of credit with Keystone Capital Partners, LLC or its affiliates. Nelson Mullins Riley & Scarborough is acting as legal counsel to CBRG. Titan Advisors has acted as capital markets advisors for Phytanix Bio, and Catherine Evans of Law Offices of Catherine Basinger Evans acted as legal advisor for Phytanix Bio.お知らせ • Jun 27Chain Bridge I Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn June 20, 2024, Chain Bridge I received written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company no longer complies with the Nasdaq Capital Market continued listing criteria set in Listing Rule 5550(a)(3), which requires the Company to maintain a minimum of 300 public holders. The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 45 calendar days, or until August 5, 2024, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, the Company will have 180 calendar days from the date of the Notice to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. While the Company can provide no assurances as to timing, the Company intends to take action to submit a plan to regain compliance within the 45 calendar day submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with Rule 5550(a)(3) within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on the Nasdaq Capital Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Nasdaq Capital Market minimum number of public holders requirement. In addition, if the Company does not meet the minimum number of public holders requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by Nasdaq staff to a hearings panel.お知らせ • Jan 07Chain Bridge I Appoints Andrew Cohen as Chief Executive OfficerChain Bridge I appointed Andrew Cohen as Chief Executive Officer of the Company.お知らせ • Jan 06Chain Bridge I Appoints Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to the BoardChain Bridge I the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by resignations.お知らせ • Oct 20Chain Bridge I Appoints David G. Brown as Director and Member of the Audit Committee and Nominating CommitteeOn October 13, 2022, Chain Bridge I announced that David G. Brown has been appointed as a director of the company and a member of the company’s audit committee and nominating committee. Mr. Brown will serve in the class of directors whose term expires at the company’s second general annual meeting of shareholders.お知らせ • Aug 06Chain Bridge I Announces Resignation of Nathaniel Fick from the Board of Directors and as a Member of its Audit Committee, Compensation Committee and Nominating CommitteeOn August 1, 2022, Nathaniel Fick resigned from the Board of Directors of Chain Bridge I (the “Company”), and as a member of the Company’s Audit Committee, Compensation Committee and Nominating Committee, effective immediately because Mr. Fick has been nominated to serve as the United States Department of State’s Ambassador at Large for Cybersecurity and Digital Policy.決済の安定と成長配当データの取得安定した配当: CBGG.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CBGG.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Chain Bridge I 配当利回り対市場CBGG.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (CBGG.F)n/a市場下位25% (US)1.4%市場トップ25% (US)4.1%業界平均 (Capital Markets)2.1%アナリスト予想 (CBGG.F) (最長3年)n/a注目すべき配当: CBGG.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CBGG.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CBGG.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CBGG.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/27 09:08終値2025/02/27 00:00収益2024/09/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Chain Bridge I 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2026, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 19Chain Bridge I Receives Notice of OTCQB Delisting and Transfer to OTCID Basic MarketAs previously disclosed, on November 12, 2025, Chain Bridge I (the “Company”) received a written notice from the OTC Markets Group (“OTC”) notifying the Company that, because the Company’s public float as it is currently displayed on the Company profile is less than 10% of the total shares outstanding, the Company is not currently in compliance with the public float requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in Section 2 of the OTCQB listing. On February 11, 2026, the Company received a written notice from OTC indicating that the cure period has now expired. Consequently, the Company’s securities were moved from the OTCQB market to the OTCID Basic Market (“OTCID”) on February 12, 2026. OTC further notified the Company that if it would like to be moved back to OTCQB, it must increase public float to at least 10% of the total shares outstanding and meet all of the eligibility requirements under Section 1 of the OTCQB listing standards. The Company will continue to file its periodic reports and remain subject to the reporting obligations under the Securities Exchange Act of 1934. The Company is actively evaluating strategic options to regain compliance with relevant listing standards and remains committed to upholding transparency and stability for all stakeholders.
お知らせ • Sep 09CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025.CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025. Under the terms of the LOI, CBRRF and CommLoan would become a combined entity, with CommLoan’s existing equity holders rolling 100% of their equity into the combined public company. Upon the closing of the transaction, the combined company will be named CommLoan Inc., and would be led by CommLoan’s founder and CEO, Mitch Ginsberg. The new company’s common stock is expected to be listed on the Nasdaq Capital Market. CBRRF expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected later in Q4 2025. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by acquirer board, approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The expected completion of the transaction is in first half of 2026.
お知らせ • Jun 22Chain Bridge I Auditor Raises 'Going Concern' DoubtChain Bridge I filed its Annual on Jun 20, 2025 for the period ending Dec 31, 2024. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
お知らせ • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2025, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 20Chain Bridge I(OTCPK:CBRR.F) dropped from NASDAQ Composite IndexChain Bridge I has been removed from NASDAQ Composite Index.
お知らせ • Nov 15Chain Bridge I announced delayed 10-Q filingOn 11/14/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 13Chain Bridge I to be Delisted from The Nasdaq Stock Market Due to Non-Compliance with Listing Rule IM-5101-2On November 12, 2024, Chain Bridge I (the ‘Company’) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (‘Rule IM-5101-2’), the staff of Nasdaq (‘Staff’) had determined that (i) the Company’s securities will be delisted from Nasdaq, (ii) trading of the Company’s Class A common stock and units will be suspended at the opening of business on November 19, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by November 4, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now subject to delisting.
お知らせ • Aug 16Chain Bridge I announced delayed 10-Q filingOn 08/15/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 23Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction.Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction on July 22, 2024. Under the terms of the Business Combination Agreement, the aggregate consideration to be paid in the Business Combination is derived from an equity value of $58 million. In addition, HoldCo will issue 17,000 shares of HoldCo Series A convertible preferred stock and issue additional shares of HoldCo preferred stock in exchange for certain short term debt obligations of the Company. HoldCo will also pay an earnout consideration which is, upon the occurrence of Triggering Event I, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 2,000,000 Earnout Shares; and upon the occurrence of Triggering Event II, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 1,000,000 Earnout Shares. Upon the closing of the business combination, and assuming no redemptions of shares of CBRG by its public stockholders, Phytanix would expect to receive up to $11 million of cash held in Trust. The business combination is not subject to a minimum cash condition. The parties intend to seek to raise additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time. Upon closing of the transaction, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PHYX.”. The new company will be led by Phytanix Bio’s founders Colin Stott, the former R&D operations director at GW Pharmaceuticals; Dominic Schiller, who formerly led GW’s external IP strategy for more than a decade; and Barrett Evans, managing director at EMC2 Capital. Mr. Barrett Evans will serve as CEO of the combined company; Mr. Colin Stott will serve as Chief Operating Officer; and Mr. Dominic Schiller will lead the legal and IP strategy. Guy Webber, a former GW preclinical team member and world-leading expert in cannabinoids/drug metabolism, will lead preclinical development for the organization. The Boards of Directors of both Phytanix Bio and CBRG have unanimously approved the proposed transaction, including a separate vote by CBRG’s independent directors. The transaction is expected to be completed in the fourth quarter of 2024, pending approval from both CBRG and Phytanix Bio shareholders, the effectiveness of the Registration Statement to be filed by HoldCo, HoldCo having at least $5,000,001 of net tangible assets, the approval by Nasdaq of HoldCo’s initial listing application in connection with the Business Combination, entry into employment agreements with certain key Company executives and entry into an agreement providing for a $100 million equity line of credit with Keystone Capital Partners, LLC or its affiliates. Nelson Mullins Riley & Scarborough is acting as legal counsel to CBRG. Titan Advisors has acted as capital markets advisors for Phytanix Bio, and Catherine Evans of Law Offices of Catherine Basinger Evans acted as legal advisor for Phytanix Bio.
お知らせ • Jun 27Chain Bridge I Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn June 20, 2024, Chain Bridge I received written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company no longer complies with the Nasdaq Capital Market continued listing criteria set in Listing Rule 5550(a)(3), which requires the Company to maintain a minimum of 300 public holders. The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 45 calendar days, or until August 5, 2024, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, the Company will have 180 calendar days from the date of the Notice to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. While the Company can provide no assurances as to timing, the Company intends to take action to submit a plan to regain compliance within the 45 calendar day submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with Rule 5550(a)(3) within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on the Nasdaq Capital Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Nasdaq Capital Market minimum number of public holders requirement. In addition, if the Company does not meet the minimum number of public holders requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by Nasdaq staff to a hearings panel.
お知らせ • Jan 07Chain Bridge I Appoints Andrew Cohen as Chief Executive OfficerChain Bridge I appointed Andrew Cohen as Chief Executive Officer of the Company.
お知らせ • Jan 06Chain Bridge I Appoints Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to the BoardChain Bridge I the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by resignations.
お知らせ • Oct 20Chain Bridge I Appoints David G. Brown as Director and Member of the Audit Committee and Nominating CommitteeOn October 13, 2022, Chain Bridge I announced that David G. Brown has been appointed as a director of the company and a member of the company’s audit committee and nominating committee. Mr. Brown will serve in the class of directors whose term expires at the company’s second general annual meeting of shareholders.
お知らせ • Aug 06Chain Bridge I Announces Resignation of Nathaniel Fick from the Board of Directors and as a Member of its Audit Committee, Compensation Committee and Nominating CommitteeOn August 1, 2022, Nathaniel Fick resigned from the Board of Directors of Chain Bridge I (the “Company”), and as a member of the Company’s Audit Committee, Compensation Committee and Nominating Committee, effective immediately because Mr. Fick has been nominated to serve as the United States Department of State’s Ambassador at Large for Cybersecurity and Digital Policy.